Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with
relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic
options of demonstrated clinical benefit.